Naltrexone directly improves epithelial barrier function by improving wound healing and reducing mucosal endoplasmic reticulum (ER) stress levels. Low dose naltrexone treatment could be considered for the treatment of therapy refractory IBD patients.

J Transl Med. 2018 Mar 9;16(1):55.

Low dose Naltrexone for induction of remission in inflammatory bowel disease patients

Click here to access the PubMed abstract of this article.

Treatment with naltrexone led to improvement in systemic and social quality of life in children with moderate to severe Crohn’s disease.

J Clin Gastroenterol. 2013 Apr;47(4):339-45.

Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn’s disease: a pilot study

Click here to access the PubMed abstract of this article.

Naltrexone improves clinical and inflammatory activity of subjects with moderate to severe Crohn’s disease compared to placebo-treated controls. Strategies to alter the endogenous opioid system provide promise for the treatment of Crohn’s disease.

Dig Dis Sci. 2011 Jul;56(7):2088-97.

Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn’s disease: a randomized placebo-controlled trial

Click here to access the PubMed abstract of this article.

Low dose naltrexone frequently has side effects but in most is tolerable. It appears to be helpful for many patients with gastrointestinal disorders.

Int J Pharm Compd. Mar-Apr 2010;14(2):171-3.

Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders

Click here to access the PubMed abstract of this article.

Low-dose naltrexone (LDN) therapy appears effective and caused no adverse side effects in subjects with active Crohn’s disease.

Am J Gastroenterol. 2007 Apr;102(4):820-8.

Low-Dose Naltrexone Therapy Improves Active Crohn’s Disease

Click here to access the PubMed abstract of this article.